AI BriefingWarp Sciences raises $215M Series A to build AI-powered robotic labs for drug discovery
·2026.11.09 09:00
Key point
The company plans to use robotic labs to generate data for AI models, creating a feedback loop that accelerates molecular synthesis and testing for pharma clients.
Details
- Warp Sciences, led by CEO Kevin Weil, has raised a $215M Series A led by Lightspeed, with participation from Premji Invest, IVP, Mayfield, and 01 Advisors.
- The company operates as a next-generation preclinical CRO in the US, providing molecular synthesis and testing infrastructure to drug development firms rather than developing its own drugs.
- Its core strategy involves using robotic labs to perform large-scale experiments and generate data for training AI models, creating a mutually reinforcing loop where better AI designs better experiments and further automation.
- The team aims to reshore key scientific capabilities from China to the US to maintain pharma industry competitiveness, starting with human chemists serving clients while gradually automating workflows by scientific discipline.
This summary was generated automatically by AI. Check the original for the author's claims and context. Copyright belongs to the original author.
Our guide explains how the AI works. Report summary errors, attribution issues, or removal requests via Contact.
Related
OpenAI Disbands Robotics Team, Pivots to General Models for Embodied AI
AI Success Now 55% Skills, 45% Connections: Why Networking Matters MoreRunway Releases Praxis-1 Open-Weight Robotics Model